Company news
Coherus Oncology, Inc. (NASDAQ:CHRS) news
Coherus Oncology, Inc. news releases on 6ix. Latest, Sep 23, 2026: Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
Press releases & updates
Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
September 23, 2026
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
August 17, 2026
Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update
August 5, 2026
Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026
July 22, 2026
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
June 23, 2026
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
May 10, 2026
Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026
May 4, 2026
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
March 8, 2026
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
March 2, 2026
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
February 17, 2026
Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock
February 12, 2026
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
February 11, 2026
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)
January 5, 2026
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma
December 8, 2025
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
November 7, 2025
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
November 6, 2025
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
November 6, 2025
Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025
October 30, 2025
Coherus Oncology to Participate in Upcoming Investor Conferences
October 23, 2025
Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 3, 2025
Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
August 7, 2025
Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA®
August 6, 2025
Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
July 31, 2025
Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics
May 30, 2025
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)
May 27, 2025
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
May 12, 2025
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025
May 5, 2025
Coherus to Participate in Upcoming Investor Conferences
May 1, 2025
Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025
April 28, 2025
Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise
April 14, 2025
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
April 1, 2025
Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting
March 25, 2025
Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
March 10, 2025
Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025
March 3, 2025
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
January 21, 2025
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
December 17, 2024
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
December 2, 2024
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
November 5, 2024
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
August 7, 2024
Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024
July 31, 2024
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
June 26, 2024
Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
June 4, 2024
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 22, 2024
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 8, 2024
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
May 8, 2024
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
May 7, 2024
Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
April 30, 2024
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 23, 2024
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
March 12, 2024